Transforming patient care with immune-based diagnostics

We have been collaborating with leading clinicians, scientists and commercial partners around the globe to develop and validate a proprietary set of rapid blood tests with the aim of empowering physicians to tackle some of the most challenging clinical dilemmas. These tests build on an exquisitely informative system – the human immune system. Using low and high-throughput molecular measurements, the application of bioinformatics and machine learning approaches, we've identified biomarkers that are key players in the body's response to different disease states. These biomarkers and algorithms are now being integrated into immunological fingerprints for decoding multiple disease states.


Sepsis is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death.  MeMed Sepsis™ is a novel host immune-based test for distinguishing between sepsis and non-infective Systemic Inflammatory Response Syndrome (SIRS) and determine disease severity. The early diagnosis of sepsis is essential for clinical intervention before the disease rapidly progresses to the more severe stages.

Despite advances in neonatal care, infection remains a leading cause of morbidity and mortality in neonates worldwide. MeMed Neo™ combines a set of proprietary immune biomarkers for distinguishing life threatening bacterial infections from mild viral infections in neonates.  

MeMed ImmunoRNA™

Over the past years, MeMed and collaborators have performed extensive measurements of the human transcriptome in various disease states using state-of-the-art high throughput technologies, and identified novel RNA-based biomarkers including mRNAs, non-coding RNAs and small RNAs. MeMed ImmunoRNA™ is a novel line of proprietary products that rely on the RNA immune response to infectious diseases and inflammatory disorders. This line of RNA based tests is suitable for the central lab but not the point-of-need. 

Reinventing pathogen-based tests

The MeMed Key platform opens the way to reinventing conventional tests by achieving central laboratory precision rapidly at the point-of-need. 

MeMed Ultra Flu™

MeMed Ultra Flu™ is a novel immunoassay for detecting influenza virus in an ultra-accurate and rapid format using a nasal sample. The test is being developed on the MeMed Key™ platform.